Date de publication: 5 novembre 2012
Promoteur – Intermédiaire Financier
B BRAUN MELSUNGEN AG RDILieu
Description
The project, covering the period 2012-2015, encompasses RDI-related expenditures focusing on formulation and carrier technology for the delivery of medicine and the supporting means necessary to develop innovative products. It will take place in Melsungen (Germany).
Objectifs
The project aims to improve quality hospital care products and treatment thanks to the availabilityof leading edge innovative treatments.
Secteur(s)
Montant BEI envisagé (montant approximatif)
EUR 80 million
Coût total (montant approximatif)
EUR 160 million
Aspects environnementaux
The R&D activities included in this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. Thus, an Environmental Impact Assessment (EIA) according to the Directive 85/337/EC, amended by Directives 97/11/EC and 2003/35/EC, is not required.
Passation des marchés
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. The promoter carries out competitive enquiries among potential suppliers for goods and services. These procedures, which are typical for the industry, are in the best interests of the project and entirely satisfactory to the Bank.
Statut
Signé - 31/05/2013
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).